Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Antipsychotic Polypharmacy Reduction Versus Polypharmacy Continuation for People With Schizophrenia." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435863/all/Sclerotherapy_for_lower_limb_telangiectasias:_Cochrane_systematic_review. Accessed 24 April 2024.
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435863/all/Sclerotherapy_for_lower_limb_telangiectasias:_Cochrane_systematic_review. Accessed April 24, 2024.
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/435863/all/Sclerotherapy_for_lower_limb_telangiectasias:_Cochrane_systematic_review
Antipsychotic Polypharmacy Reduction Versus Polypharmacy Continuation for People With Schizophrenia [Internet]. In: Cochrane Abstracts. [cited 2024 April 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435863/all/Sclerotherapy_for_lower_limb_telangiectasias:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
ID - 435863
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435863/all/Sclerotherapy_for_lower_limb_telangiectasias:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -